Adam Buckley Email

SVP Business Development . VBI Vaccines

Current Roles

Employees:
101
Revenue:
$15.7M
About
VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B with the only 3-antigen hepatitis B vaccine, Sci-B-Vac®, which is approved for use and commercially available in Israel, and recently completed its Phase 3 program in the U.S., Europe, and Canada, and with an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI's enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI's lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic pan-coronavirus vaccine candidate. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel. To learn more, visit: www.vbivaccines.com News and Insights: www.vbivaccines.com/wire/ Investors: www.vbivaccines.com/investors/ Job Opportunities: www.vbivaccines.com/about/careers/
VBI Vaccines Address
160 Second Street
Cambridge, MA
United States
VBI Vaccines Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.